On February 17, 2026 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, reported a broad expansion of its global intellectual property (IP) estate, including newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas. These additions strengthen the company’s protection around iopofosine I 131, its proprietary radiotherapeutic, as well as its broader portfolio, including CLR 125, the company’s Auger-emitting radiopharmaceutical in development as a treatment for triple negative breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are seeing meaningful and timely momentum across our global IP estate at a truly pivotal moment for the company," said James Caruso, president and CEO of Cellectar Biosciences. "Securing these patents in major international markets reinforces the uniqueness of our technology and provides critical intellectual property fortification. Following guidance from the EMA’s Scientific Advice Working Party (SAWP) we are advancing our planned filing for conditional marketing authorization of iopofosine I 131 for Waldenström macroglobulinemia in Europe. This strengthened global protection is essential to our long-term commercial strategy—and, more importantly, it supports our commitment to delivering new, desperately needed therapeutic options to patients who continue to face limited treatment choices."
The expanded IP coverage spans multiple patent families critical to the company’s therapeutic and platform strategies:
Ether and Alkyl Phospholipid Compounds for Treating Cancer and Imaging Cancer Stem Cells
Covers iopofosine I 131 and CLR-125 for both therapeutic use and imaging/detection of primary tumors and cancer stem cells.
Newly issued in Europe, China, Israel, Eurasia, and New Zealand.
Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer
Covers proprietary iopofosine I 131 dosing regimens.
Newly issued in Eurasia, Israel, Turkey, Mexico, and Canada.
(Press release, Cellectar Biosciences, FEB 17, 2026, View Source [SID1234662706])